0.70
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Is Verrica Pharmaceuticals Inc. stock a good hedge against inflationOver 200% growth - jammulinksnews.com
Verrica Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - Autocar Professional
What analysts say about Verrica Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Reverse Stock Split - TipRanks
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split - Investing.com
Is Verrica Pharmaceuticals Inc. a good long term investmentAccelerated earnings growth - jammulinksnews.com
What drives Verrica Pharmaceuticals Inc. stock priceFree Predictions - jammulinksnews.com
Published on: 2025-07-19 07:38:47 - jammulinksnews.com
Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialAnalyst Grade Signals - Newser
What institutions are buying Verrica Pharmaceuticals Inc. stock nowDaily Trade Opportunity - Newser
What makes Verrica Pharmaceuticals Inc. stock price move sharplyInsider Strategy Insight - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - newser.com
How Verrica Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Community - Newser
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Average Target Price from Brokerages - Defense World
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates - MyChesCo
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% – Should You Sell? - Defense World
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 | VRCA Stock News - GuruFocus
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales - Investing.com
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Commo - GuruFocus
Verrica Pharmaceuticals Receives Milestone Payments and Initiates Global Phase 3 Trial for YCANTH® Treatment of Common Warts - Quiver Quantitative
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - The Manila Times
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest - Defense World
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results - Barchart.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages - Defense World
Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):